Literature DB >> 21486206

Synthesis and antimycobacterial evaluation of N'-(E)-heteroaromaticpyrazine-2-carbohydrazide derivatives.

C H S Lima1, M G M O Henriques, A L P Candéa, M C S Lourenço, F A F M Bezerra, M L Ferreira, C R Kaiser, M V N de Souza.   

Abstract

A series of nine N'-(E)-heteroaromatic-pyrazine-2-carbohydrazide derivatives (5a-f and 6a-c) have been synthesized and evaluated against M. tuberculosis ATCC 27294 using the micro plate Alamar Blue assay (MABA), being the activities expressed as the minimum inhibitory concentration (MIC) in µg/ml. Compounds 5a and 5f exhibited potent activities (3.12 and 50µg/mL, respectively) when compared to the first line drug pyrazinamide (MIC>100 µg/mL). Afterwards, these compounds were evaluated for their cell viabilities in non-infected and infected macrophages with Mycobaterium bovis Bacillus Calmette-Guerin (BCG) and 5f was not cytotoxic to host cells in the effective concentration to inhibit the growth of M. tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21486206     DOI: 10.2174/157340611795564303

Source DB:  PubMed          Journal:  Med Chem        ISSN: 1573-4064            Impact factor:   2.745


  3 in total

1.  When biomolecules meet 2-hydrazinopyrazine: from theory through experiment to molecular levels using a wide spectrum of techniques.

Authors:  Paulina Mech; Mariusz Makowski; Anna Kawiak; Agnieszka Chylewska
Journal:  RSC Adv       Date:  2020-11-09       Impact factor: 4.036

2.  Biological evaluation of isoniazid derivatives as an anticancer class.

Authors:  Felipe A R Rodrigues; Augusto C A Oliveira; Bruno C Cavalcanti; Claudia Pessoa; Alessandra C Pinheiro; Marcus V N de Souza
Journal:  Sci Pharm       Date:  2013-09-22

3.  3-Substituted N-Benzylpyrazine-2-carboxamide Derivatives: Synthesis, Antimycobacterial and Antibacterial Evaluation.

Authors:  Lucia Semelková; Ondřej Janďourek; Klára Konečná; Pavla Paterová; Lucie Navrátilová; František Trejtnar; Vladimír Kubíček; Jiří Kuneš; Martin Doležal; Jan Zitko
Journal:  Molecules       Date:  2017-03-21       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.